CANbridge consolidates its gene therapy portfolio
BEIJING AND BURLINGTON, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, engaged in the research, development and commercialization of transformative therapies to treat rare diseases and oncology, announced that it has exercised its option to obtain exclusive worldwide rights to develop, manufacture and commercialize a novel second-generation gene therapy …
CANbridge consolidates its gene therapy portfolio Read More »
